C4 Therapeutics Past Earnings Performance
Past criteria checks 0/6
C4 Therapeutics's earnings have been declining at an average annual rate of -25.3%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been declining at an average rate of 23.3% per year.
Key information
-25.3%
Earnings growth rate
76.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -23.3% |
| Return on equity | -48.8% |
| Net Margin | -629.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched
Mar 01Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts
Feb 29
C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Feb 24New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)
Nov 03Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week
May 14C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors
Sep 29C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M
Aug 04Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00
May 10C4 Therapeutics: Poor Data Destroyed Preclinical Promise
May 04C4 Therapeutics closes $181M capital raise
Jun 21C4 Therapeutics gets dosing underway in early-stage CFT7455 lymphoma trial
Jun 14C4 Therapeutics nears three-month high on pre-clinical data for lung cancer therapy
Jun 07Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 62%
Jun 02C4 Therapeutics to advance CFT8919 into IND-enabling studies
May 26Revenue & Expenses BreakdownBeta
How C4 Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 20 | -126 | 41 | -7 |
| 31 Dec 23 | 21 | -132 | 42 | 0 |
| 30 Sep 23 | 20 | -135 | 42 | 0 |
| 30 Jun 23 | 16 | -140 | 41 | 0 |
| 31 Mar 23 | 27 | -131 | 41 | 0 |
| 31 Dec 22 | 31 | -128 | 43 | 0 |
| 30 Sep 22 | 48 | -107 | 41 | 0 |
| 30 Jun 22 | 50 | -99 | 40 | 0 |
| 31 Mar 22 | 46 | -95 | 39 | 0 |
| 31 Dec 21 | 46 | -84 | 33 | 0 |
| 30 Sep 21 | 34 | -80 | 31 | 1 |
| 30 Jun 21 | 34 | -82 | 26 | 1 |
| 31 Mar 21 | 34 | -73 | 20 | 1 |
| 31 Dec 20 | 33 | -66 | 15 | 1 |
| 30 Sep 20 | 33 | -67 | 11 | 0 |
| 30 Jun 20 | 30 | -52 | 11 | 0 |
| 31 Mar 20 | 24 | -47 | 10 | 0 |
| 31 Dec 19 | 21 | -43 | 9 | 0 |
| 31 Dec 18 | 19 | -24 | 7 | 0 |
Quality Earnings: CCCC is currently unprofitable.
Growing Profit Margin: CCCC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CCCC is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.
Accelerating Growth: Unable to compare CCCC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CCCC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.9%).
Return on Equity
High ROE: CCCC has a negative Return on Equity (-48.81%), as it is currently unprofitable.